Effect of olmesartan on diurnal blood pressure profile, vascular function, oxidative stress, and renal renin-angiotensin system in hypertensives with chronic kidney disease

Effect of olmesartan on diurnal blood pressure profile, vascular function, oxidative stress, and renal renin-angiotensin system in hypertensives with chronic kidney disease - Effects of olmesartan on hypertensives with CKD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000944

Enrollment

200

Registered

2008-11-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with chronic kidney disease

Interventions

Olmesartan group: To achieve blood pressure control below 130/80 mmHg, start with once-daily dosing of olmesartan 5-10 mg, and increase up to 10-40 mg if effect of olmesartan on the clinical paramet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Casual Blood pressure >= 130/80. 2) Chronic kidney disease >= stage 1 (>= microalbunuria).

Exclusion criteria

Exclusion criteria: 1) Pregnant women, or women suspected of being pregnant. 2) Hyperkalemia. 3) Bilateral renal artery stenosis. 4) History of hypersensitivity to the administered olmesartan.

Design outcomes

Primary

Measure	Time frame
1) Abdominal circumference 2) Casual blood pressure, home blood pressure. 3) Diurnal blood pressure profile by ambulatory blood pressure monitoring. 4) Glucose metabolism: FPG, IRI, HbA1c. 5) Renal function: Urinary protein excretion, BUN, urinary creatinine excretion, urinary albumin excretion, eGFR, urinary type IV collagen excretion. 6) Lipid metabolism: total cholesterol, LDL cholesterol, tryglyceride, HDL-choresterol. 7) Cardiac function: BNP. 8) Vascular function: ABI/PWV, FMD. 9) Inflamation and oxidative stress marker: hs-CRP, adiponectin, plasma apelin, urinary 8-OHdG. 10) Markers of intra-renal renin-angiotensin system: plasma and urinary angiotensinogen. 11) Genotype of renin-angiotensin system: angiotensinogen, renin, AT1 receptor, ATRAP, Nedd4L. 12) Examination of renal biopsy specimen (glomerular sclerosis, fibrosis, and expression of ATRAP and AT1 receptor mRNA and protein).	—

Measure

Time frame

1) Abdominal circumference 2) Casual blood pressure, home blood pressure. 3) Diurnal blood pressure profile by ambulatory blood pressure monitoring. 4) Glucose metabolism: FPG, IRI, HbA1c. 5) Renal function: Urinary protein excretion, BUN, urinary creatinine excretion, urinary albumin excretion, eGFR, urinary type IV collagen excretion. 6) Lipid metabolism: total cholesterol, LDL cholesterol, tryglyceride, HDL-choresterol. 7) Cardiac function: BNP. 8) Vascular function: ABI/PWV, FMD. 9) Inflamation and oxidative stress marker: hs-CRP, adiponectin, plasma apelin, urinary 8-OHdG. 10) Markers of intra-renal renin-angiotensin system: plasma and urinary angiotensinogen. 11) Genotype of renin-angiotensin system: angiotensinogen, renin, AT1 receptor, ATRAP, Nedd4L. 12) Examination of renal biopsy specimen (glomerular sclerosis, fibrosis, and expression of ATRAP and AT1 receptor mRNA and protein).

—

Countries

Japan

Contacts

Public ContactKazuaki Uchino

Yokohama City University Hospital Department of Cardiorenal Medicine

mai_mew963@hotmail.com045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026